---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Schrödinger

🌎 schrodinger.com

Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools for drug discovery and materials science. Founded in 1990 and headquartered in New York, Schrödinger's platform supports biopharmaceutical and industrial research globally, with a commitment to innovation in molecular discovery and design.

---

Schrödinger - Latest News and Updates

• Schrödinger's stock is skyrocketing in 2025 as the market favors smaller companies with a market value between $1 billion and $5 billion.
• Schrödinger's stock surged 15% as the company integrates AI into its drug discovery platform, supported by partnerships with Novartis and Nvidia, and anticipates clinical data from its first three internal drugs.
• Schrödinger will host a webinar on January 23 to introduce their FEP+ Residue Scan tool, which speeds up protein engineering processes by 15 times without losing accuracy.
• Peter J. Skrdla, Executive Director at Schrödinger, highlighted potential errors in kinetic analysis when using DSC for complex solid-state chemical reactions.
• Schrödinger Suite is a key tool for computational chemistry researchers with expertise in drug discovery and structure-based drug design.

• Martin Vögele, a Senior Scientist at Schrödinger, contributed to a perspective on drug delivery challenges and guidelines for comparing permeability measurements across different methods.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.